{"name":"Seres Therapeutics","slug":"seres-therapeutics","ticker":"MCRB","exchange":"NASDAQ","domain":"serestherapeutics.com","description":"Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres","hq":"Cambridge, MA","founded":0,"employees":"66","ceo":"","sector":"Microbiome Therapeutics","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":7.99,"stockChange":0.23,"stockChangePercent":2.96,"marketCap":"$77M","metrics":{"revenue":1147000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":-46899000,"cash":29834000,"dividendYield":0,"peRatio":-0.8,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"SER-155","genericName":"SER-155","slug":"ser-155","indication":"Other","status":"phase_1"},{"name":"SER-262","genericName":"SER-262","slug":"ser-262","indication":"Other","status":"phase_1"},{"name":"Vancomycin Pre-Treat","genericName":"Vancomycin Pre-Treat","slug":"vancomycin-pre-treat","indication":"Other","status":"phase_1"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"SER-109","genericName":"SER-109","slug":"ser-109","indication":"Recurrent Clostridioides difficile infection (rCDI) in adults","status":"phase_3"}]}],"pipeline":[{"name":"SER-109","genericName":"SER-109","slug":"ser-109","phase":"phase_3","mechanism":"SER-109 is a spore-based microbiome therapeutic that restores healthy gut bacterial composition to prevent recurrent Clostridioides difficile infection.","indications":["Recurrent Clostridioides difficile infection (rCDI) in adults"],"catalyst":""},{"name":"SER-155","genericName":"SER-155","slug":"ser-155","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SER-262","genericName":"SER-262","slug":"ser-262","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Vancomycin Pre-Treat","genericName":"Vancomycin Pre-Treat","slug":"vancomycin-pre-treat","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":1,"phase_1":3},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":789000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":789000},{"period":"2024-12-31","value":0},{"period":"2023-12-31","value":0},{"period":"2022-12-31","value":0}],"grossProfit":-5755000,"grossProfitHistory":[{"period":"2025-12-31","value":-5755000},{"period":"2024-12-31","value":-3532000},{"period":"2023-12-31","value":0},{"period":"2022-12-31","value":0}],"rdSpend":49060000,"rdSpendHistory":[{"period":"2025-12-31","value":49060000},{"period":"2024-12-31","value":64600000},{"period":"2023-12-31","value":117597000},{"period":"2022-12-31","value":109651000}],"sgaSpend":39156000,"operatingIncome":-93971000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-93971000},{"period":"2024-12-31","value":-121315000},{"period":"2023-12-31","value":-195097000},{"period":"2022-12-31","value":-179914000}],"netIncome":5696000,"netIncomeHistory":[{"period":"2025-12-31","value":5696000},{"period":"2024-12-31","value":136000},{"period":"2023-12-31","value":-113724000},{"period":"2022-12-31","value":-250157000}],"eps":0.64,"epsHistory":[{"period":"2025-12-31","value":0.64},{"period":"2024-12-31","value":0},{"period":"2023-12-31","value":-17.77},{"period":"2022-12-31","value":-46.2}],"cash":45766000,"cashHistory":[{"period":"2025-12-31","value":45766000},{"period":"2024-12-31","value":30793000},{"period":"2023-12-31","value":127965000},{"period":"2022-12-31","value":163030000}],"totalAssets":138193000,"totalLiabilities":93975000,"totalDebt":82966000,"equity":44218000,"operatingCashflow":1117000,"operatingCashflowHistory":[{"period":"2025-12-31","value":1117000},{"period":"2024-12-31","value":-148609000},{"period":"2023-12-31","value":-117354000},{"period":"2022-12-31","value":-228816000}],"capex":-252000,"capexHistory":[{"period":"2025-12-31","value":-252000},{"period":"2024-12-31","value":-380000},{"period":"2023-12-31","value":-7975000},{"period":"2022-12-31","value":-9821000}],"freeCashflow":865000,"dividendsPaid":null,"buybacks":null,"employees":66,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":7539000,"ebit":80290000,"ebitda":81244000,"period":"2025-12-31","revenue":789000,"epsBasic":null,"netIncome":-15335000,"rdExpense":11684000,"epsDiluted":null,"grossProfit":197000,"operatingIncome":-19377000},{"sga":9476000,"ebit":-22477000,"ebitda":-21433000,"period":"2025-09-30","revenue":0,"epsBasic":0.94,"netIncome":8204000,"rdExpense":12616000,"epsDiluted":0.94,"grossProfit":-736000,"operatingIncome":-22477000},{"sga":10253000,"ebit":-19855000,"ebitda":-18796000,"period":"2025-06-30","revenue":0,"epsBasic":-2.27,"netIncome":-19855000,"rdExpense":12939000,"epsDiluted":-2.27,"grossProfit":-1689000,"operatingIncome":-24881000},{"sga":11888000,"ebit":32682000,"ebitda":33758000,"period":"2025-03-31","revenue":0,"epsBasic":3.76,"netIncome":32682000,"rdExpense":11821000,"epsDiluted":3.75,"grossProfit":-3527000,"operatingIncome":-27236000},{"sga":12462000,"ebit":-15637000,"ebitda":-14552000,"period":"2024-12-31","revenue":0,"epsBasic":null,"netIncome":-15637000,"rdExpense":12841000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-28835000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":11.63,"netIncome":null,"rdExpense":null,"epsDiluted":11.63,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":7.99,"previousClose":7.76,"fiftyTwoWeekHigh":29.98,"fiftyTwoWeekLow":6.53,"fiftyTwoWeekRange":"6.53 - 29.98","fiftyDayAverage":8.51,"twoHundredDayAverage":14.26,"beta":0,"enterpriseValue":125812328,"forwardPE":-0.8,"priceToBook":1.73,"priceToSales":67.46,"enterpriseToRevenue":109.69,"enterpriseToEbitda":-1.5,"pegRatio":0,"ebitda":-83804000,"ebitdaMargin":0,"freeCashflow":-40485248,"operatingCashflow":-42153000,"totalDebt":80499000,"debtToEquity":303.8,"currentRatio":1.65,"returnOnAssets":-38.9,"returnOnEquity":-121.9,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":1,"targetMeanPrice":22,"targetHighPrice":22,"targetLowPrice":22,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":11.8,"institutionHeldPercent":26.3,"sharesOutstanding":9683934,"floatShares":7358337,"sharesShort":540750,"shortRatio":10.62,"shortPercentOfFloat":5.6,"epsTrailing":-5.2,"epsForward":-10.28,"revenuePerShare":0.13,"bookValue":4.63,"officers":[{"age":69,"name":"Mr. Richard N. Kender B.S., M.B.A.","title":"Interim CEO & Executive Chair"},{"age":50,"name":"Dr. Matthew R. Henn Ph.D.","title":"President & Chief Scientific Officer"},{"age":58,"name":"Ms. Marella  Thorell CPA","title":"Executive VP, CFO & Treasurer"},{"age":70,"name":"Mr. Thomas J. DesRosier Esq., J.D.","title":"Executive VP, Chief Legal Officer & Secretary"},{"age":41,"name":"Ms. Kelly  Brady M.S.","title":"Executive VP & COO"},{"age":null,"name":"Mr. Chris  McChalicher","title":"Executive VP & CTO"},{"age":null,"name":"Dr. Dennis M. Walling M.D.","title":"Senior VP of Clinical Development & Head of Clinical Research"},{"age":null,"name":"Ms. Ann  Kurowski","title":"Senior Vice President of Regulatory Affairs"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.serestherapeutics.com","phone":"617 945 9626"}}